IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and price targets for IDEAYA Biosciences and Longeveron, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEAYA Biosciences | 1 | 1 | 14 | 0 | 2.81 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
IDEAYA Biosciences presently has a consensus price target of $53.42, suggesting a potential upside of 47.89%. Longeveron has a consensus price target of $80.00, suggesting a potential upside of 4,931.45%. Given Longeveron’s higher possible upside, analysts plainly believe Longeveron is more favorable than IDEAYA Biosciences.
Insider and Institutional Ownership
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares IDEAYA Biosciences and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEAYA Biosciences | -75.93% | -16.73% | -15.34% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Earnings & Valuation
This table compares IDEAYA Biosciences and Longeveron”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEAYA Biosciences | $218.71 million | 14.51 | -$113.70 million | ($1.94) | -18.62 |
| Longeveron | $1.20 million | 4.23 | -$22.70 million | ($9.90) | -0.16 |
Longeveron has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
Summary
IDEAYA Biosciences beats Longeveron on 10 of the 14 factors compared between the two stocks.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
